Literature DB >> 22772542

Trial failure prompts soul-searching for critical-care specialists.

Elie Dolgin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22772542     DOI： 10.1038/nm0712-1000

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  3 in total

1.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

2.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Authors:  Edward Abraham; Pierre-François Laterre; Rekha Garg; Howard Levy; Deepak Talwar; Benjamin L Trzaskoma; Bruno François; Jeffrey S Guy; Martina Brückmann; Alvaro Rea-Neto; Rolf Rossaint; Dominique Perrotin; Armin Sablotzki; Nancy Arkins; Barbara G Utterback; William L Macias
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

3.  Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

Authors:  Simon Nadel; Brahm Goldstein; Mark D Williams; Heidi Dalton; Mark Peters; William L Macias; Shamel A Abd-Allah; Howard Levy; Robinette Angle; Dazhe Wang; David P Sundin; Brett Giroir
Journal:  Lancet       Date:  2007-03-10       Impact factor: 79.321
  3 in total
  11 in total

Review 1.  Innate response activator B cells: origins and functions.

Authors:  Benjamin G Chousterman; Filip K Swirski
Journal:  Int Immunol       Date:  2015-05-08       Impact factor: 4.823

2.  The wingless-related integration site-5a/secreted frizzled-related protein-5 system is dysregulated in human sepsis.

Authors:  D M Schulte; D Kragelund; N Müller; I Hagen; G Elke; A Titz; D Schädler; J Schumacher; N Weiler; B Bewig; S Schreiber; M Laudes
Journal:  Clin Exp Immunol       Date:  2015-04       Impact factor: 4.330

Review 3.  Sepsis, oxidative stress, and hypoxia: Are there clues to better treatment?

Authors:  David Bar-Or; Matthew M Carrick; Charles W Mains; Leonard T Rael; Denetta Slone; Edward N Brody
Journal:  Redox Rep       Date:  2015-03-24       Impact factor: 4.412

4.  Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis.

Authors:  Georg F Weber; Benjamin G Chousterman; Shun He; Ashley M Fenn; Manfred Nairz; Atsushi Anzai; Thorsten Brenner; Florian Uhle; Yoshiko Iwamoto; Clinton S Robbins; Lorette Noiret; Sarah L Maier; Tina Zönnchen; Nuh N Rahbari; Sebastian Schölch; Anne Klotzsche-von Ameln; Triantafyllos Chavakis; Jürgen Weitz; Stefan Hofer; Markus A Weigand; Matthias Nahrendorf; Ralph Weissleder; Filip K Swirski
Journal:  Science       Date:  2015-03-13       Impact factor: 47.728

Review 5.  Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach.

Authors:  Richard S Hotchkiss; Guillaume Monneret; Didier Payen
Journal:  Lancet Infect Dis       Date:  2013-03       Impact factor: 25.071

Review 6.  Therapeutic interventions in sepsis: current and anticipated pharmacological agents.

Authors:  Prashant Shukla; G Madhava Rao; Gitu Pandey; Shweta Sharma; Naresh Mittapelly; Ranjita Shegokar; Prabhat Ranjan Mishra
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 7.  Are there any benefits from statin treatment for the septic patient?

Authors:  Peter S Kruger; Bala Venkatesh
Journal:  Curr Atheroscler Rep       Date:  2014-01       Impact factor: 5.113

8.  Pharmacokinetics of Standard- and Reduced-Dose Recombinant Human Soluble Thrombomodulin in Patients with Septic Disseminated Intravascular Coagulation during Continuous Hemodiafiltration.

Authors:  Eizo Watanabe; Shingo Yamazaki; Daisuke Setoguchi; Tomohito Sadahiro; Yoshihisa Tateishi; Tatsuya Suzuki; Itsuko Ishii; Shigeto Oda
Journal:  Front Med (Lausanne)       Date:  2017-02-21

9.  Reactivation of multiple viruses in patients with sepsis.

Authors:  Andrew H Walton; Jared T Muenzer; David Rasche; Jonathan S Boomer; Bryan Sato; Bernard H Brownstein; Alexandre Pachot; Terrence L Brooks; Elena Deych; William D Shannon; Jonathan M Green; Gregory A Storch; Richard S Hotchkiss
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

10.  The Yin and Yang of Tyrosine Kinase Inhibition During Experimental Polymicrobial Sepsis.

Authors:  Cassiano Felippe Gonçalves-de-Albuquerque; Ina Rohwedder; Adriana Ribeiro Silva; Alessandra Silveira Ferreira; Angela R M Kurz; Céline Cougoule; Sarah Klapproth; Tanja Eggersmann; Johnatas D Silva; Gisele Pena de Oliveira; Vera Luiza Capelozzi; Gabriel Gutfilen Schlesinger; Edlaine Rijo Costa; Rita de Cassia Elias Estrela Marins; Attila Mócsai; Isabelle Maridonneau-Parini; Barbara Walzog; Patricia Rieken Macedo Rocco; Markus Sperandio; Hugo Caire de Castro-Faria-Neto
Journal:  Front Immunol       Date:  2018-04-30       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.